MK-677

Discussion in 'Human Growth Hormone and Peptides' started by mands, Mar 22, 2017.

  1. mands

    mands Member AnabolicLab.com Supporter

    Here is a few studies on MK-677. It's been a topic of conversation as of late.

    Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J1, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA.
    Author information

    Abstract
    Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion and body composition in otherwise healthy obese males. The study was randomized, double blind, parallel, and placebo controlled. Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks. Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo). Serum IGF-binding protein-3 was also significantly increased (P < or = 0.001 vs. placebo). GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677. Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment. The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo). Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05). Total and visceral fat were not significantly changed with active therapy. The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1). Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks. We conclude that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3. The effects on cortisol secretion were transient. Changes in body composition and energy expenditure were of an anabolic nature, with a sustained increase in fat-free mass and a transient increase in basal metabolic rate. Further studies are needed to evaluate whether a higher dose of MK-677 or a more prolonged treatment period can promote a reduction in body fat.

    PMID:

    9467542

    DOI:

    10.1210/jcem.83.2.4539
    Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
    Svensson J1, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA.
    Author information

    Abstract
    The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK-677 on markers of bone metabolism was determined in healthy obese male subjects. This was a randomized, double-blind, parallel, placebo-controlled study. Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks. MK-677 increased markers of bone formation; a 23% increase in the carboxy-terminal propeptide of type I procollagen levels and a 28% increase in procollagen III peptide levels were seen with as little as 2 weeks of MK-677 treatment (p < 0.01 and p = 0.001 vs. placebo, respectively) while a 15% increase in serum levels of osteocalcin was not detected until 8 weeks of treatment (p < 0.01 vs. placebo). Markers of bone resorption were induced within 2 weeks of treatment with MK-677; serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen were increased 26% at 8 weeks (p = 0.001 vs. placebo), and urine hydroxyproline/creatinine and calcium/creatinine ratios at 8 weeks were increased by 23% (p < 0.05 vs. placebo) and 46% (p < 0.05 vs placebo), respectively, MK-677 increased serum insulin-like growth factor binding protein-5 (IGFBP-5) by 43-44% after 2-8 weeks of treatment (p < 0.01 vs. placebo). Serum IGFBP-4 was increased by 25% after 2 weeks of treatment (p < 0.001 vs. placebo) but no significant change from baseline was observed after 8 weeks of treatment. Plasma interleukin-6 was not significantly changed by active treatment. In conclusion, short-term treatment of healthy obese male volunteers with the GH secretagogue MK-677 increases markers of both bone resorption and formation. Large increases in serum levels of igf-1 and IGFBP-5 and a transient increase in serum IGFBP-4 were found. Future long-term studies are needed to investigate if prolonged treatment with MK-677 increases bone mass.

    PMID:

    9661080

    DOI:

    10.1359/jbmr.1998.13.7.1158
    [Indexed for MEDLINE]
    Free full text

    J Bone Miner Res. 1999 Jul;14(7):1182-8.
    Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG1, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ.
    Author information

    Abstract
    Growth hormone (GH) stimulates osteoblasts in vitro and increases bone turnover and stimulates osteoblast activity when given to elderly subjects. Probably a major effect of GH on bone is mediated through stimulation of either circulating or locally produced insulin-like growth factor I (IGF-I). We determined the effect of chronic administration of the GH secretagogue, MK-677, on serum IGF-I and markers of bone turnover in 187 elderly adults (65 years or older) enrolled in three randomized, double-blind, placebo-controlled clinical studies lasting 2-9 weeks. Urine was collected for determination of N-telopeptide cross-links (NTXs), a marker of bone resorption, and blood was collected for determination of serum osteocalcin and bone-specific alkaline phosphatase (BSAP), as bone formation markers, and serum IGF-I levels pre- and post-treatment. Dose response data were initially obtained in healthy elderly subjects who received oral doses of 10 mg or 25 mg of MK-677 or placebo for 2 weeks (n = 10-12/group). Treatment with 10 mg and 25 mg of MK-677 for 2 weeks increased mean urine NTXs 10% and 17%, respectively (p < 0.05 vs. placebo). Additionally, 50 healthy elderly subjects received either placebo (n = 20) for 4 weeks or 25 mg of MK-677 (n = 30) daily for 2 weeks followed by 50 mg daily for 2 weeks. MK-677 increased mean serum osteocalcin by 8% (p < 0.05 vs. placebo). In both studies, MK-677 increased serum IGF-I levels significantly (55-94%). Subsequently, the biological effects of MK-677 were studied in 105 elderly subjects who met objective criteria for functional impairment. Subjects were randomized to receive oral doses of placebo for 9 weeks or either 5, 10, or 25 mg of MK-677 daily for an initial 2 weeks followed by 25 mg of MK-677 daily for the next 7 weeks(n = 63 on MK-677 and n = 28 on placebo completed 9 weeks of therapy). Treatment with MK-677 (all MK-677 groups combined) for 9 weeks increased mean serum osteocalcin by 29.4% and BSAP by 10.4% (p < 0.001 vs. placebo) and mean urinary NTX excretion by 22.6% (p < 0.05 vs. placebo). The change from baseline serum osteocalcin correlated with the change from baseline serum IGF-I in the MK-677 group (r = 0.37; p < 0.01). In conclusion, once daily dosing with MK-677, an orally active GH secretagogue, stimulates bone turnover in elderly subjects based on elevations in biochemical markers of bone resorption and formation.

    mands
     
  2. GetBig0087

    GetBig0087 Member

    I'm running it now at 20MG a day and I'll see what happens. I know it's a long game with this one. If all goes well and I actually see progress I'll continue it. No numbness of hands or sleeplessness as of yet. I'm always hungry so that side effect won't go noticed.
     
    mands likes this.
  3. JayWaWa

    JayWaWa Member

    I run it daily, i love the stuff. Its equivalent to 2-3 iu dose for me. Im a good secretor i guess lol.
     
  4. nickels

    nickels Member

    My first two weeks of running it at 12.5 mg/day, the hunger was nuts.

    It seems to have tapered off now. Also, I'm pretty sure I'm seeing similar effects to when I was running low-dose exogenous GH.
     
    TorroXL likes this.
  5. @mands

    Out of curiosity, what are your opinions on MK-677, and this study?
     
  6. Wunderpus

    Wunderpus Member AnabolicLab.com Supporter

    How have you determined this?
     
    Dr JIM and theprodgicalson like this.
  7. JayWaWa

    JayWaWa Member

    i determine it by my blood serums but also how i feel compared to my use of exogenous gh at about the same dosage.
     
    theprodgicalson likes this.
  8. Wunderpus

    Wunderpus Member AnabolicLab.com Supporter

    I'd like to see more data, if you have it... I.e. bloods while on 2-3ius, natty bloods and bloods on MK-677. By the way, I'm not doubting you, I'm genuinely interested.
     
  9. mands

    mands Member AnabolicLab.com Supporter

    So far I was intrigued enough to order 200 tabs. All three studies seem to be pretty consistent with one another.

    I have seen some blood work from few and it seems to be working by raising igf-1 significantly.

    mands
     
    scoobs88 and colossus25 like this.
  10. thrombus

    thrombus Member

    How much are you taking? The effect you're getting is exactly what I'm interested in.
     
  11. Sampei

    Sampei Member AnabolicLab.com Supporter

    Do you mind sharing the source? :) You can PM me if you want to keep it private.
     
    fodsod likes this.
  12. Sampei

    Sampei Member AnabolicLab.com Supporter

    Would you take the MK with HGH or when you don't use HGH?

    Before bed or at wake up?
    I was thinking of use it when I do few months off the HGH, especially because i'm traveling for work for 3-4 months and I can't bring around vials of HGH but the MK would be a nice solution.

    How long one have to use it? 2-3 months and then take sometime off?
     
    fodsod likes this.
  13. mands

    mands Member AnabolicLab.com Supporter

    Taking them both together would be ultimate for raising those igf-1 levels up and cheaper than running a higher GH amount.

    I would just take it at night along with your GH injections.

    Yes if you are gone for that amount of time I would run the MK. 20mg a day should keep you around 40% above baseline.

    I would take a month or so off between MK cycles.

    mands
     
  14. fodsod

    fodsod Member

    If I could find a reliable/affordable source I'd run it year round with and without GH. I've done it both ways and it's a nice addition with or without GH. I'm curious what (if any) long term effects might be but it seems pretty safe.
     
    DrankSlangin, TorroXL, TRT and 2 others like this.
  15. mands

    mands Member AnabolicLab.com Supporter

    I would be more concerned about the problems that occur with high level igf-1 levels than anything else with this drug from research I've seen.

    You are correct we just don't know the long term effects of MK but we do know long term effects of increased IGF-1 levels.

    mands
     
  16. Sampei

    Sampei Member AnabolicLab.com Supporter

    Care to chime on the side effect.of long high igf level?

    Organs growth?

     
    oswaldo salcedo likes this.
  17. mands

    mands Member AnabolicLab.com Supporter

    Yes sir! Even short term ones as well. This includes blood glucose issues and how the body processes sugars and fats. Abnormal soft tissue growth, enlarged organs, high levels of triglycerides that can cause diabetes and heart disease. Also can accelerate pre-existing tumors.

    I think it's a good idea to cycle off higher amounts of GH and get those igf-1 levels in normal range for a couple months.

    mands
     
    Alemxzx, BNGgrowth, scoobs88 and 5 others like this.
  18. stone988

    stone988 Member

    With any study I always ask where was it done, what country? and who paid for it? Also this was done on unhealthy individuals and diet of the subjects wasn't even mentioned. Neither was it done under any physical stress or exercise. I say as interesting as the study is its totally useless and inconclusive to anything we are trying to do here as far as athletics. Healthy obese males? are you kidding me lol. Removing sugar from their diets would give a more drastic change lol I find what members on the board say about a compound to be more reliable then a study like this. But thanks for posting
     
  19. mands

    mands Member AnabolicLab.com Supporter

    Healthy obese would mean someone like me. They use the BMI chart.

    I guess you skipped right over the healthy elderly study I posted. Someone like you. lol

    I can dig up more for you if you would like.

    Removing sugar from their diet will give you a 40% in igf-1? lol

    mands
     
  20. Ripped

    Ripped Member

    What's up with that bro. This is @mands thread if he didn't think it was relevant I'm sure he would not have posted it . I guess you prefer bro science?

    Sent from my SAMSUNG-SM-G900A using Tapatalk